Suheung Co., Ltd. (008490.KS)
KRW 12880.0
(-1.68%)
KRW 12880.0
(-1.68%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 56.03 Billion KRW | -25.59% |
| 2022 | 75.3 Billion KRW | 32.97% |
| 2021 | 56.62 Billion KRW | 21.4% |
| 2020 | 46.64 Billion KRW | 6.1% |
| 2019 | 43.96 Billion KRW | 25.65% |
| 2018 | 34.98 Billion KRW | -0.6% |
| 2017 | 35.2 Billion KRW | 8.88% |
| 2016 | 32.33 Billion KRW | 10.19% |
| 2015 | 29.34 Billion KRW | 9.07% |
| 2014 | 26.9 Billion KRW | 5.09% |
| 2013 | 25.59 Billion KRW | -1.0% |
| 2012 | 25.85 Billion KRW | 24.31% |
| 2011 | 20.8 Billion KRW | -7.72% |
| 2010 | 22.54 Billion KRW | 30.03% |
| 2009 | 17.33 Billion KRW | 23.17% |
| 2008 | 14.07 Billion KRW | 24.6% |
| 2007 | 11.29 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 16.94 Billion KRW | 26.81% |
| 2024 Q1 | 14.07 Billion KRW | -3.12% |
| 2023 Q4 | 14.52 Billion KRW | 198.19% |
| 2023 FY | 56.03 Billion KRW | -25.59% |
| 2023 Q1 | 14.18 Billion KRW | -32.39% |
| 2023 Q2 | -14.42 Billion KRW | -201.72% |
| 2023 Q3 | -14.79 Billion KRW | -2.55% |
| 2022 Q2 | 18.85 Billion KRW | -1.6% |
| 2022 Q3 | 16.31 Billion KRW | -13.49% |
| 2022 Q4 | 20.97 Billion KRW | 28.6% |
| 2022 Q1 | 19.16 Billion KRW | 47.4% |
| 2022 FY | 75.3 Billion KRW | 32.97% |
| 2021 Q3 | 17.09 Billion KRW | 21.92% |
| 2021 Q4 | 12.99 Billion KRW | -23.96% |
| 2021 FY | 56.62 Billion KRW | 21.4% |
| 2021 Q1 | 12.51 Billion KRW | -2.68% |
| 2021 Q2 | 14.02 Billion KRW | 12.04% |
| 2020 Q1 | 11.36 Billion KRW | -13.07% |
| 2020 FY | 46.64 Billion KRW | 6.1% |
| 2020 Q4 | 12.85 Billion KRW | 16.09% |
| 2020 Q3 | 11.07 Billion KRW | -2.4% |
| 2020 Q2 | 11.34 Billion KRW | -0.12% |
| 2019 FY | 43.96 Billion KRW | 25.65% |
| 2019 Q4 | 13.06 Billion KRW | 28.72% |
| 2019 Q3 | 10.15 Billion KRW | -3.75% |
| 2019 Q1 | 10.19 Billion KRW | 46.12% |
| 2019 Q2 | 10.54 Billion KRW | 3.5% |
| 2018 Q2 | 9.51 Billion KRW | 12.0% |
| 2018 Q3 | 10 Billion KRW | 5.22% |
| 2018 Q4 | 6.97 Billion KRW | -30.31% |
| 2018 FY | 34.98 Billion KRW | -0.6% |
| 2018 Q1 | 8.49 Billion KRW | -9.19% |
| 2017 FY | 35.2 Billion KRW | 8.88% |
| 2017 Q4 | 9.35 Billion KRW | 7.46% |
| 2017 Q3 | 8.7 Billion KRW | -0.36% |
| 2017 Q2 | 8.73 Billion KRW | 3.88% |
| 2017 Q1 | 8.4 Billion KRW | -2.72% |
| 2016 FY | 32.33 Billion KRW | 10.19% |
| 2016 Q4 | 8.64 Billion KRW | 10.57% |
| 2016 Q3 | 7.81 Billion KRW | -5.69% |
| 2016 Q2 | 8.29 Billion KRW | 9.41% |
| 2016 Q1 | 7.57 Billion KRW | -0.84% |
| 2015 Q3 | 7.57 Billion KRW | -0.05% |
| 2015 FY | 29.34 Billion KRW | 9.07% |
| 2015 Q1 | 6.55 Billion KRW | -4.19% |
| 2015 Q2 | 7.57 Billion KRW | 15.64% |
| 2015 Q4 | 7.64 Billion KRW | 0.92% |
| 2014 FY | 26.9 Billion KRW | 5.09% |
| 2014 Q4 | 6.83 Billion KRW | 4.95% |
| 2014 Q3 | 6.51 Billion KRW | -6.5% |
| 2014 Q2 | 6.96 Billion KRW | 5.87% |
| 2014 Q1 | 6.58 Billion KRW | 12.1% |
| 2013 Q1 | 6.43 Billion KRW | -2.95% |
| 2013 Q2 | 6.35 Billion KRW | -1.19% |
| 2013 FY | 25.59 Billion KRW | -1.0% |
| 2013 Q4 | 5.87 Billion KRW | -15.38% |
| 2013 Q3 | 6.93 Billion KRW | 9.15% |
| 2012 Q3 | 6.82 Billion KRW | 11.36% |
| 2012 Q2 | 6.12 Billion KRW | 53.27% |
| 2012 Q4 | 6.62 Billion KRW | -2.88% |
| 2012 FY | 25.85 Billion KRW | 24.31% |
| 2012 Q1 | 3.99 Billion KRW | 0.0% |
| 2011 Q2 | 2.91 Billion KRW | 1.37% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 20.8 Billion KRW | -7.72% |
| 2011 Q1 | 2.87 Billion KRW | 0.0% |
| 2011 Q3 | 3.02 Billion KRW | 3.57% |
| 2010 Q2 | 3.06 Billion KRW | 9.99% |
| 2010 FY | 22.54 Billion KRW | 30.03% |
| 2010 Q1 | 2.79 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q3 | 3.06 Billion KRW | -0.01% |
| 2009 Q2 | 2.54 Billion KRW | -5.59% |
| 2009 Q1 | 2.69 Billion KRW | 0.0% |
| 2009 FY | 17.33 Billion KRW | 23.17% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q3 | 3.01 Billion KRW | 18.52% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 FY | 14.07 Billion KRW | 24.6% |
| 2008 Q2 | 2.72 Billion KRW | 3.26% |
| 2008 Q3 | 2.95 Billion KRW | 8.42% |
| 2008 Q1 | 2.64 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | 11.29 Billion KRW | 0.0% |
| 2007 Q3 | 2.53 Billion KRW | -0.19% |
| 2007 Q1 | 2.26 Billion KRW | 0.0% |
| 2007 Q2 | 2.54 Billion KRW | 12.38% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -18.577% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 81.197% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 79.876% |
| HANDOK Inc. | 153.76 Billion KRW | 63.561% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | 19.045% |
| Yuhan Corporation | 489.94 Billion KRW | 88.564% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 81.746% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -34.082% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 90.829% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | 22.16% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 67.825% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -39.894% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 40.106% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 51.16% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -18.577% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -31.928% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 25.34% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | 4.454% |
| JW Holdings Corporation | 301.25 Billion KRW | 81.401% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 78.528% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 86.289% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 76.547% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 56.112% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | 17.975% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | 14.782% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 67.968% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -18.577% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 77.508% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 90.002% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 76.547% |
| Yuhan Corporation | 489.94 Billion KRW | 88.564% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 71.067% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | 19.342% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 76.547% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 55.668% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 52.601% |
| CKD Bio Corp. | 25.19 Billion KRW | -122.387% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 74.76% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 66.064% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | 15.636% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 56.112% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 84.024% |
| Boryung Corporation | 285.16 Billion KRW | 80.351% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 35.994% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 67.825% |
| JW Lifescience Corporation | 20.26 Billion KRW | -176.543% |